To further elucidate the underlying mechanisms of treatment response and resistance, we investigated immunosuppression within the tumor microenvironment (TME) by assessing expression of PD-1, Tim-3 and CD39 on tumor-infiltrating CD4+ and CD8+ T cells. This evidence concerns the gene ENTPD1 and neoplasm.